Danielle Gerhard, PhD | Mar 22, 2024 | 10+ min read
With the help of directed evolution, scientists inch closer to developing viral vectors that can cross the human blood-brain barrier to deliver gene therapy.
By forging new relationships and finding novel uses for existing technologies, this year’s top companies are employing creative ways to advance their science.
Tired of dancing to the tunes of international funders, and doubtful that long-promised national grants will come, a handful of African biomedical scientists have turned to private investors to bankroll their dreams of autonomy in the lab.
In Chapter 13, “Trusting Experts—and the Trump Administration,” Marc Zimmer laments the communication breakdown between modern US policy makers and scientists